Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed's current Lead Director, who is not standing for reelection at the company's 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.

GlobeNewsWire • Aug 17, 2026

Dividend Champion, Contender, And Challenger Highlights: Week August 16

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Seeking Alpha • Aug 14, 2026

ResMed Q4 Earnings Call Highlights

ResMed NYSE: RMD reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electronic components and freight.

MarketBeat • Aug 9, 2026

Top 50 High-Quality Dividend Growth Stocks For August 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. The universe delivered a 10.44% YTD return through July, closely matching SPY but trailing SCHD, with several individual stocks significantly outperforming. Currently, 40 stocks in the universe offer a forward return estimate of at least 10%, with 25 appearing potentially undervalued based on free cash flow analysis.

Seeking Alpha • Aug 9, 2026

ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

Shares of ResMed dropped about 6% in morning trade on Friday after the medtech company forecast fiscal 2027 revenue below Wall ​Street expectations, impacted by suspended ventilator sales and cost pressures.

Reuters • Aug 7, 2026

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

Zacks Investment Research • Aug 7, 2026

ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis  Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70% Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.

GlobeNewsWire • Aug 6, 2026

ResMed (RMD) Q4 Earnings and Revenues Top Estimates

ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.9 per share. This compares to earnings of $2.55 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Aug 5, 2026